Roche: Q1 2013 Results (Roche) - Apr 12, 2013 - Anticipated regulatory submission in US for type 2 diabetes in 2015; Anticipated regulatory submission in China for type 2 diabetes in 2015; Anticipated regulatory submission in US for cardiovascular risk reduction in post acute coronary syndrome patients with type 2 diabetes in 2015; Anticipated regulatory submission in EU for cardiovascular risk reduction in post acute coronary syndrome patients with type 2 diabetes in 2015; Anticipated regulatory submission in US for cardiovascular risk reduction in patients with stable cardiovascular disease and type 2 diabetes/pre-type 2 diabetes in 2016 or after; Anticipated regulatory submission in EU for cardiovascular risk reduction in patients with stable cardiovascular disease and type 2 diabetes/pre-type 2 diabetes in 2016 or after
Anticipated EU regulatory • Anticipated FDA event • Anticipated non-US regulatory • Diabetes
|